Lenalidomide capsule

DRUG4 trials

Sponsors

GWT-TUD GmbH, Ida Bruun Kristensen, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Stichting Hemato-Oncologie voor Volwassenen Nederland

Conditions

B-cell Non-Hodgkin's LymphomaMultiple MyelomaPancreas CancerPancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma

Phase 1

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

CompletedNCT04257448

GWT-TUD GmbHPancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma

Start: 2020-05-25End: 2024-07-02Updated: 2025-09-30

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.B-cell Non-Hodgkin's Lymphoma

Start: 2023-05-31End: 2025-11-30Target: 102Updated: 2023-05-24

Phase 2

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruitingNCT04717700

Ida Bruun KristensenMultiple Myeloma

Start: 2021-08-18End: 2029-06-01Target: 50Updated: 2025-03-18

Phase 3

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

RecruitingNCT06187441

Stichting Hemato-Oncologie voor Volwassenen NederlandMultiple Myeloma

Start: 2024-05-14End: 2037-12-31Target: 599Updated: 2024-08-19

Related Papers

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Blood2025-11-03

Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma.

Journal of Clinical Oncology2025-05-28

Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Blood2024-11-05

Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT195: Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nab-paclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

Cancer Research2023-04-141 citations